1. Scrip
  2. >>Therapy Areas

Ferring Hails World First Positive Phase III Data For Microbiome Product

US Filing Planned For Later This Year

 
• By Kevin Grogan

Preliminary efficacy findings from an ongoing pivotal study of Ferring's RBX2660 showed that the first-in-class microbiota-based therapy helped restore the gut microbiome and break the cycle of recurrence of C diff. infection.

Leading
Ferring Out In Front In The Microbiome Field • Source: Shutterstock

It has been a long wait but Ferring Pharmaceuticals AS has reported the world’s first positive Phase III results for any microbiome-based therapy with its non-antibiotic RBX2660 closing in on a filing for reducing recurrent Clostridioides difficile (C diff) infection in adults.

The Swiss firm's Rebiotix Inc. subsidiary has announced preliminary positive efficacy findings from an ongoing pivotal study of RBX2660 which showed that the first-in-class microbiota-based therapy helped restore the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.